Andrade JG, Verma A, Mitchell LB, et al; CCS Atrial Fibrillation Guidelines Committee. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018 Nov;34(11):1371-1392. doi: 10.1016/j.cjca.2018.08.026. PubMed PMID: 30404743.
January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4. PubMed PMID: 24682347; PubMed Central PMCID: PMC4676081.
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec;10(12):1932-63. doi: 10.1016/j.hrthm.2013.05.014. Epub 2013 Aug 30. Review. PubMed PMID: 24011539.
Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug;34(29):2281-329. doi: 10.1093/eurheartj/eht150. Epub 2013 Jun 24. PubMed PMID: 23801822.
American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013 May 7;127(18):1916-26. doi: 10.1161/CIR.0b013e318290826d. Epub 2013 Apr 1. PubMed PMID: 23545139.
Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1. PubMed PMID: 22922413.
Tracy CM, Epstein AE, Darbar D, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012 Oct 2;126(14):1784-800. doi: 10.1161/CIR.0b013e3182618569. Epub 2012 Sep 10. Erratum in: Circulation. 2013 Jan 22;127(3):e357-9. Heart Rhythm Society [added]. PubMed PMID: 22965336.
Pediatric and Congenital Electrophysiology Society (PACES); Heart Rhythm Society (HRS); American College of Cardiology Foundation (ACCF); American Heart Association (AHA); American Academy of Pediatrics (AAP); Canadian Heart Rhythm Society (CHRS), Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm. 2012 Jun;9(6):1006-24. doi: 10.1016/j.hrthm.2012.03.050. Epub 2012 May 10. PubMed PMID: 22579340.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172. PubMed PMID: 20802247.
Definition, Etiology, PathogenesisTop
Atrioventricular nodal reentrant tachycardia (AVNRT) is a paroxysmal tachycardia that occurs in patients with dual atrioventricular (AV) node physiology, as they have both a fast nodal pathway with a longer refractory period and a slow nodal pathway with a shorter refractory period. It is most commonly observed in individuals with no underlying structural heart disease.
Types of AVNRT:
1) Typical and most common type of AVNRT: Anterograde conduction (from the atrium to the ventricle) proceeds over the slow pathway and retrograde conduction (from the ventricle to the atrium) proceeds over the fast pathway (slow-fast AVNRT).
2) Atypical AVNRT: Anterograde conduction proceeds over the fast pathway and retrograde conduction proceeds over the slow pathway (fast-slow AVNRT).
Clinical Features and Natural HistoryTop
AVNRT usually occurs in young patients, causing paroxysmal palpitations that abruptly start and stop. The palpitations are usually relatively well tolerated, as no concomitant structural heart disease is found and the heart rates are usually ≤170 to 180 beats/min. Patients may describe a sensation of rapid regular pounding in the neck during tachycardia. The attacks may be frequent (up to several a day) and may require emergency care.
Electrocardiography (ECG): Typical AVNRT is characterized by the absence of evident P waves, which are hidden in or present immediately after the QRS complex (short RP interval) but may distort the terminal portion of the QRS by mimicking an S wave in the inferior leads or an r wave in lead V1. In atypical AVNRT the RP interval is long (RP interval > PR interval). In both typical and atypical AVNRTs the P waves are negative in the inferior leads.
Classification of antiarrhythmic drugs: see Table 3.4-1.
Antiarrhythmic agents: see Table 3.4-2.
1. Termination of an AVNRT attack:
1) Vagal maneuvers (eg, Valsalva,Evidence 1Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Low Quality of Evidence (low confidence that we know true effects of the intervention). Quality of Evidence lowered due to imprecision. Smith GD, Fry MM, Taylor D, Morgans A, Cantwell K. Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia. Cochrane Database Syst Rev. 2015 Feb 18;(2):CD009502. doi: 10.1002/14651858.CD009502.pub3. Review. PubMed PMID: 25922864. carotid massage, and facial immersion in cold water) should be initiated to terminate the arrhythmia or to modify AV conduction.
2) IV adenosine as a bolus of 6 mg. If not effective, 12 or 18 mg can be given after 1 to 2 minutes.
3) IV beta-blockers, diltiazem, or verapamil are a reasonable option in stable patients.
4) Direct current cardioversion should be performed for acute treatment in hemodynamically unstable patients.
2. Recurrence prevention:
1) In patients with frequently recurring AVNRT attacks who prefer long-term oral treatment to ablation, use diltiazem, verapamil, or a beta–blocker.
2) In patients with no structural heart disease who do not respond to drugs that inhibit AV node conduction (see above), use flecainide or propafenone.
3) In minimally symptomatic patients with AVNRT, clinical follow-up without pharmacologic therapy or ablation is reasonable.
4) In patients with poorly tolerated AVNRT, recurrent attacks, and significant symptoms, as well as in those with mild and well-tolerated symptoms who wish to achieve a complete cure of AVNRT, catheter ablation of the slow pathway is indicated. This is the most successful treatment method, although associated with a low risk (0.5%-1%) of AV block requiring pacemaker implantation.